Purpose: To investigate the expression and function of Galectin-3 (Gal-3) in CD133+ pulmonary adenocarcinoma. Methods: CD133+ pulmonary adenocarcinoma cells were separated by MACS from excised pulmonary adenocarci- noma specimens of 11 patients. The percentage of CD133+ cells in different cells population was determined by flow cytometry (FCM). Expression of Gal-3 in cancer cells was detected by Fluorescence Quantitation RT-PCR (FQRT- PCR) and Western blot whereas extracellular expression was detected by ELISA. CD133+ cells were transfected with Gal-3 specific siRNA to explore the affects of Gal-3 inhibition on cancer cell growth and induction of CD8+ T cell apoptosis. Results: Cells expressing CD133 constituted 90% of the CD133+ subpopulation after separation by MACS whereas they made up only 1.2% of the unsorted cell population. Expression of Gal-3 was 1.24 fold, 1.5 fold and 2 fold higher in CD133+ cells than in CD133- cells as detected by FQRT-PCR, Western blot and ELISA respectively (p<0.05 for each). The supernatants of CD133+ cells induced apop- tosis of CD8+ T cells to a greater degree (27.1±2.6%) compared with supernatants from CD133-cells (10.1±2.2%), and could be down-regulated by lactose, anti-galectin-3 polyclonal antibody and Gal-3 siRNA. Downregulation of Gal-3 resulted in significant inhibition of cancer cell growth in vitro. Conclusion: Gal-3 is expressed at a relatively higher level in CD133+ lung adenocarcinoma cells and could induce CD8+ T cell apoptosis in vitro, both of which could be down-regulated by Gal-3 siRNA. These findings indicate that Gal-3 may play an important role during oncogenesis, implying a potential therapeutic target for pulmonary ade- nocarcinoma. © 2010 CIM.
CITATION STYLE
Wan, L., Wang, J. J., Zhou, X. F., & Zhao, F. (2010). CD133+ human pulmonary adenocarcinoma cells induce apoptosis of CD8+T cells by highly expressed galectin-3. Clinical and Investigative Medicine, 33(1). https://doi.org/10.25011/cim.v33i1.11837
Mendeley helps you to discover research relevant for your work.